Skip to main content
. 2019 Dec 17;7:353. doi: 10.1186/s40425-019-0771-1

Table 3.

Safety and efficacy analysis of HIV and HBV/HCV cohorts

Cohorts (N) ORRa
N (%)
Any Grade irAEs
N (%)
Grade ≥ 3 irAEs
N (%)
HIV (21) 2 CR/3 PR (28) 5 (24) 3 (14)
HBV/HCV (34) 6 PR (18) 15 (44) 10 (29)b

aResponse evaluable patients HIV: 18; HBV/HCV: 34, b Two patients with baseline grade ≥ 2 hepatitis